

# H Clifford Lane

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2159442/publications.pdf>

Version: 2024-02-01

215  
papers

41,881  
citations

11908

72  
h-index

2823

197  
g-index

220  
all docs

220  
docs citations

220  
times ranked

59431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <i>Clinical Trials</i> , 2022, 19, 52-61.	0.7	16
2	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet</i> , The, 2022, 399, 530-540.	6.3	48
3	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 622-635.	4.6	135
4	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	2.0	56
5	RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	17
6	Association of Lower Exposure Risk With Paucisymptomatic/Asymptomatic Infection, Less Severe Disease, and Unrecognized Ebola Virus Disease: A Seroepidemiological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac052.	0.4	7
7	DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021Åupdate). <i>Nucleic Acids Research</i> , 2022, 50, W216-W221.	6.5	1,694
8	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. <i>Aids</i> , 2022, Publish Ahead of Print, .	1.0	7
9	QuasiSeq: profiling viral quasispecies via self-tuning spectral clustering with PacBio long sequencing reads. <i>Bioinformatics</i> , 2022, 38, 3192-3199.	1.8	3
10	A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. <i>Annals of Internal Medicine</i> , 2022, 175, 969-979.	2.0	99
11	Research in the Context of a Pandemic. <i>New England Journal of Medicine</i> , 2021, 384, 755-757.	13.9	50
12	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. <i>Annals of Internal Medicine</i> , 2021, 174, 93-95.	2.0	38
13	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 619-629.	13.9	741
14	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	13.9	357
15	Characterization of Ebola Virusâ€Associated Eye Disease. <i>JAMA Network Open</i> , 2021, 4, e2032216.	2.8	12
16	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. <i>Aids</i> , 2021, 35, 193-204.	1.0	6
17	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	2.9	24
18	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1898-1906.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	1.9	6
20	SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. <i>Annals of Internal Medicine</i> , 2021, 174, 687-690.	2.0	64
21	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1151-1158.	2.0	16
22	Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 960-965.	0.6	3
23	The impact of the 2014 Ebola epidemic on HIV disease burden and outcomes in Liberia West Africa. <i>PLoS ONE</i> , 2021, 16, e0257049.	1.1	0
24	Natural Occurring Polymorphisms in HIV-1 Integrase and RNase H Regulate Viral Release and Autoprocessing. <i>Journal of Virology</i> , 2021, 95, e0132321.	1.5	7
25	Tackling the burden of mumps in the military: A report of the Defense Health Board. <i>Vaccine</i> , 2021, 39, 6186-6188.	1.7	0
26	Partnership for Research on Ebola VACCination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. <i>Trials</i> , 2021, 22, 86.	0.7	9
27	Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa613.	0.4	6
28	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. <i>Aids</i> , 2021, 35, 783-789.	1.0	2
29	Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1 <sup>hi</sup> /low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2020, 221, 523-533.	1.9	5
30	Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2317-2324.	2.9	10
31	Four Decades of HIV/AIDS – Much Accomplished, Much to Do. <i>New England Journal of Medicine</i> , 2020, 383, 1-4.	13.9	106
32	Defective HIV-1 proviruses produce viral proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3704-3710.	3.3	150
33	Covid-19 – Navigating the Uncharted. <i>New England Journal of Medicine</i> , 2020, 382, 1268-1269.	13.9	1,393
34	An observational prospective cohort study of the epidemiology of hospitalized patients with acute febrile illness in Indonesia. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007927.	1.3	20
35	Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	13.9	5,834
36	Adult and paediatric haematology and clinical chemistry laboratory reference limits for Liberia. <i>African Journal of Laboratory Medicine</i> , 2020, 9, 1080.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 941-950.	5.2	83
38	Evaluation of an antibody to $\hat{1}\pm$ <sub>4</sub> $\hat{1}^2$ <sub>7</sub> in the control of SIVmac239- <i>nef-stop</i> infection. <i>Science</i> , 2019, 365, 1025-1029.	6.0	29
39	An open-label phase 1 clinical trial of the anti- $\hat{1}\pm$ <sub>4</sub> $\hat{1}^2$ <sub>7</sub> monoclonal antibody vedolizumab in HIV-infected individuals. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	40
40	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 951-963.	5.2	99
41	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-“Naive” Participants From the Strategic Timing of AntiRetroviral Treatment Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1325-1334.	1.9	18
42	A Longitudinal Study of Ebola Sequelae in Liberia. <i>New England Journal of Medicine</i> , 2019, 380, 924-934.	13.9	104
43	A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. <i>New England Journal of Medicine</i> , 2019, 381, 2293-2303.	13.9	1,171
44	A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	21
45	Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 207-215.	0.9	1
46	PREVAIL I Cluster Vaccination Study With rVSV $\hat{1}$ ”G-ZEBOV-GP as Part of a Public Health Response in Liberia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1634-1641.	1.9	12
47	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. <i>JCI Insight</i> , 2019, 4, .	2.3	6
48	Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation. <i>Journal of Neuroinflammation</i> , 2018, 15, 207.	3.1	9
49	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2186-2196.	1.3	4
50	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	13.9	314
51	Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox. <i>Scientific Reports</i> , 2017, 7, 43441.	1.6	20
52	Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 500-511.	5.2	85
53	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	13.9	199
54	Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. <i>Lancet Infectious Diseases</i> , 2017, 17, 1255-1265.	4.6	70

#	ARTICLE	IF	CITATIONS
55	STING is an essential mediator of the Ku70-mediated production of IFN- $\lambda$ 1 in response to exogenous DNA. <i>Science Signaling</i> , 2017, 10, .	1.6	100
56	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx262.	0.4	65
57	CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies. <i>PLoS ONE</i> , 2017, 12, e0187912.	1.1	2
58	IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion. <i>JCI Insight</i> , 2017, 2, .	2.3	15
59	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0167091.	1.1	38
60	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1448-1456.	13.9	429
61	Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8783-8788.	3.3	282
62	Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients. <i>Aids</i> , 2016, 30, 2487-2493.	1.0	26
63	INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 574-578.	1.9	22
64	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2928-2937.	1.3	7
65	Conducting clinical trials in outbreak settings: Points to consider. <i>Clinical Trials</i> , 2016, 13, 92-95.	0.7	35
66	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	0.7	63
67	Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 450.	0.3	4
68	Activated platelet-T-cell conjugates in peripheral blood of patients with HIV infection. <i>Aids</i> , 2015, 29, 1297-1308.	1.0	45
69	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , 2015, 373, 795-807.	13.9	2,232
70	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 74-82.	0.8	571
71	HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls. <i>Journal of AIDS &amp; Clinical Research</i> , 2014, 05, .	0.5	5
72	Chronic Exposure to Type-I IFN under Lymphopenic Conditions Alters CD4 T Cell Homeostasis. <i>PLoS Pathogens</i> , 2014, 10, e1003976.	2.1	24

#	ARTICLE	IF	CITATIONS
73	A Model of Federal Interagency Cooperation: The National Interagency Confederation for Biological Research. <i>Biosecurity and Bioterrorism</i> , 2014, 12, 144-150.	1.2	5
74	Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. <i>Aids</i> , 2014, 28, 1091-1099.	1.0	56
75	siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. <i>Nucleic Acids Research</i> , 2014, 42, 583-598.	6.5	30
76	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1104-1110.	1.3	13
77	Plasma Interleukin-27 (IL-27) Levels Are Not Modulated in Patients with Chronic HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e98989.	1.1	14
78	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. <i>PLoS ONE</i> , 2014, 9, e101785.	1.1	31
79	Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 571-577.	3.2	28
80	Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. <i>Biochemical and Biophysical Research Communications</i> , 2013, 434, 228-234.	1.0	43
81	Enhanced Effector Function of CD8+ T Cells From Healthy Controls and HIV-Infected Patients Occurs Through Thrombin Activation of Protease-Activated Receptor 1. <i>Journal of Infectious Diseases</i> , 2013, 207, 638-650.	1.9	38
82	IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. <i>Journal of Experimental Medicine</i> , 2013, 210, 517-534.	4.2	66
83	Interleukin-2 Inhibits HIV-1 Replication in Some Human T Cell Lymphotropic Virus-1-infected Cell Lines via the Induction and Incorporation of APOBEC3G into the Virion. <i>Journal of Biological Chemistry</i> , 2013, 288, 17812-17822.	1.6	13
84	Cerebrospinal Fluid HIV-1 Compartmentalization in a Patient With AIDS and Acute Varicella-Zoster Virus Meningomyelradiculitis. <i>Clinical Infectious Diseases</i> , 2013, 57, e135-e142.	2.9	18
85	Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults. <i>Aids</i> , 2013, 27, 591-595.	1.0	17
86	HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127. <i>Aids</i> , 2013, 27, 1867-1877.	1.0	18
87	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. <i>PLoS ONE</i> , 2013, 8, e57121.	1.1	54
88	Regulatory T Cells in HIV-1 Infection: The Good, the Bad, and the Ugly. <i>Journal of Infectious Diseases</i> , 2012, 205, 1479-1482.	1.9	21
89	DAVID-WS: a stateful web service to facilitate gene/protein list analysis. <i>Bioinformatics</i> , 2012, 28, 1805-1806.	1.8	955
90	The CD8 <sup>+</sup> HLA-DR <sup>+</sup> T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. <i>European Journal of Immunology</i> , 2012, 42, 2608-2620.	1.6	30

#	ARTICLE	IF	CITATIONS
91	The role of cytokines in the pathogenesis and treatment of HIV infection. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 207-214.	3.2	68
92	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e44454.	1.1	456
93	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. <i>PLoS ONE</i> , 2012, 7, e24243.	1.1	89
94	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 36-43.	0.9	142
95	IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. <i>Blood</i> , 2011, 118, 6845-6848.	0.6	84
96	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. <i>Blood</i> , 2011, 117, 4787-4795.	0.6	165
97	Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. <i>Blood</i> , 2011, 118, 262-270.	0.6	40
98	Cutting Edge: Ku70 Is a Novel Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN. <i>Journal of Immunology</i> , 2011, 186, 4541-4545.	0.4	211
99	Clinical Evaluation of the Potential Utility of Computational Modeling as an HIV Treatment Selection Tool by Physicians with Considerable HIV Experience. <i>AIDS Patient Care and STDs</i> , 2011, 25, 29-36.	1.1	20
100	Biomarkers in HIV disease. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 459-462.	1.5	9
101	Interferon- $\beta$ Produces Significant Decreases in HIV Load. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 461-464.	0.5	37
102	Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2010, 18, 2-6.	2.9	30
103	Identification and Characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx Recombinant Subtypes in Mali, West Africa. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 45-55.	0.5	9
104	IL-15 acts as a potent inducer of CD4 <sup>+</sup> CD25 <sup>hi</sup> cells expressing FOXP3. <i>European Journal of Immunology</i> , 2008, 38, 1621-1630.	1.6	64
105	Effects of Delays in Peripheral Blood Processing, Including Cryopreservation, on Detection of CD31 Expression on Naïve CD4 T Cells. <i>Vaccine Journal</i> , 2008, 15, 1141-1143.	3.2	1
106	IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. <i>Aids</i> , 2008, 22, 39-45.	1.0	86
107	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19851-19856.	3.3	111
108	CD4 T Cell Survival after Intermittent Interleukin-2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2008, 198, 843-850.	1.9	18

#	ARTICLE	IF	CITATIONS
109	Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. <i>Blood</i> , 2008, 112, 287-294.	0.6	243
110	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203.	3.9	1,398
111	Infections in the immunocompromised host. , 2008, , 477-491.		0
112	DAVID gene ID conversion tool. <i>Bioinformatics</i> , 2008, 2, 428-430.	0.2	156
113	DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. <i>Nucleic Acids Research</i> , 2007, 35, W169-W175.	6.5	1,934
114	Loss of Naïve Cells Accompanies Memory CD4 + T-Cell Depletion during Long-Term Progression to AIDS in Simian Immunodeficiency Virus-Infected Macaques. <i>Journal of Virology</i> , 2007, 81, 893-902.	1.5	50
115	CD4+T Cell Responses to Interleukin-2 Administration in HIV-1 Infected Patients Are Directly Related to the Baseline Level of Immune Activation. <i>Journal of Infectious Diseases</i> , 2007, 196, 677-683.	1.9	15
116	Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. <i>Blood</i> , 2007, 109, 1841-1849.	0.6	94
117	Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. <i>Blood</i> , 2007, 110, 501-508.	0.6	51
118	DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. <i>BMC Bioinformatics</i> , 2007, 8, 426.	1.2	510
119	Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. <i>Aids</i> , 2006, 20, 361-369.	1.0	13
120	Decreased CD127 Expression on T Cells in HIV-1-infected Adults Receiving Antiretroviral Therapy With or Without Intermittent IL-2 Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 537-544.	0.9	24
121	A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK "Vanguard Study. <i>PLOS Clinical Trials</i> , 2006, 1, e3.	3.5	19
122	Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1523.	3.8	18
123	Functional Correlation between a Novel Amino Acid Insertion at Codon 19 in the Protease of Human Immunodeficiency Virus Type 1 and Polymorphism in the p1/p6 Gag Cleavage Site in Drug Resistance and Replication Fitness. <i>Journal of Virology</i> , 2006, 80, 6136-6145.	1.5	26
124	A Transcription Inhibitor, Actinomycin D, Enhances HIV-1 Replication Through an Interleukin-6-Dependent Pathway. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 388-397.	0.9	9
125	Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. <i>Human Gene Therapy</i> , 2005, 16, 1065-1074.	1.4	69
126	Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. <i>Journal of Clinical Investigation</i> , 2005, 115, 2139-2148.	3.9	115



#	ARTICLE	IF	CITATIONS
127	In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. <i>Journal of Clinical Investigation</i> , 2005, 115, 1839-1847.	3.9	109
128	Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. <i>Human Gene Therapy</i> , 2005, .	1.4	0
129	CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. <i>Clinical Infectious Diseases</i> , 2004, 39, 115-122.	2.9	109
130	Immune-based Therapies for HIV Infection. , 2004, , 931-945.		0
131	BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. <i>Clinical Immunology</i> , 2004, 113, 248-255.	1.4	10
132	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. <i>Blood</i> , 2004, 103, 3282-3286.	0.6	47
133	IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. <i>Blood</i> , 2004, 104, 775-780.	0.6	93
134	A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ t cells. <i>Clinical Immunology</i> , 2003, 106, 188-196.	1.4	21
135	DAVID: Database for Annotation, Visualization, and Integrated Discovery. <i>Genome Biology</i> , 2003, 4, 1.	3.8	1,411
136	A Randomized, Double-Blinded, Placebo-Controlled Trial of Intermittent Administration of Interleukin-2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2003, 188, 531-536.	1.9	13
137	Macrophage-Tropic Simian/Human Immunodeficiency Virus Chimeras Use CXCR4, Not CCR5, for Infections of Rhesus Macaque Peripheral Blood Mononuclear Cells and Alveolar Macrophages. <i>Journal of Virology</i> , 2003, 77, 13042-13052.	1.5	37
138	Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression. <i>Journal of Virology</i> , 2003, 77, 1011-1020.	1.5	20
139	Cutting Edge: L-Selectin (CD62L) Expression Distinguishes Small Resting Memory CD4+ T Cells That Preferentially Respond to Recall Antigen. <i>Journal of Immunology</i> , 2003, 170, 28-32.	0.4	101
140	Incomplete CD4 T Cell Recovery in HIV-1 Infection After 12 Months of Highly Active Antiretroviral Therapy Is Associated With Ongoing Increased CD4 T Cell Activation and Turnover. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 125-133.	0.9	110
141	Increases in CD4+ T Lymphocytes Occur Without Increases in Thymic Size in HIV-Infected Subjects Receiving Interleukin-2 Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 299-303.	0.9	10
142	DAVID: Database for Annotation, Visualization, and Integrated Discovery. <i>Genome Biology</i> , 2003, 4, P3.	3.8	4,682
143	Increasing CD4+T Cells Specific for Tuberculosis Correlate with Improved Clinical Immunity after Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 969-975.	0.5	20
144	Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10712-10717.	3.3	65

#	ARTICLE	IF	CITATIONS
145	Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13813-13818.	3.3	22
146	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of $\geq 300/\text{mm}^3$ : CPCRA 059. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 221-231.	0.9	32
147	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of $\geq 300/\text{mm}^3$ : CPCRA 059. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 221-231.	0.9	34
148	High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults. <i>Annals of Internal Medicine</i> , 2002, 137, 17.	2.0	153
149	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. <i>Blood</i> , 2002, 100, 2159-2167.	0.6	69
150	The Evaluation of Subcutaneous Proleukin <sup>®</sup> (interleukin-2) in a Randomized International Trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 198-220.	2.0	81
151	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. <i>Blood</i> , 2002, 100, 2159-2167.	0.6	2
152	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. <i>Blood</i> , 2002, 100, 2159-67.	0.6	19
153	Cytokine-based therapies for HIV infection. <i>Aids</i> , 2001, 15, S183-S191.	1.0	5
154	CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. <i>Aids</i> , 2001, 15, 1765-1775.	1.0	50
155	Bioterrorism: A clear and present danger. <i>Nature Medicine</i> , 2001, 7, 1271-1273.	15.2	157
156	Amino Acid Deletion at Codon 67 and Thr-to-Gly Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Novel Drug Resistance Profiles. <i>Journal of Virology</i> , 2001, 75, 3988-3992.	1.5	32
157	Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV. <i>Journal of Experimental Medicine</i> , 2001, 194, 1731-1741.	4.2	203
158	A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. <i>Aids</i> , 2000, 14, 2509-2513.	1.0	33
159	Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 183.	3.8	158
160	High-Level Resistance to 3- <sup>2</sup> -Azido-3- <sup>2</sup> -Deoxythymidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2000, 74, 1023-1028.	1.5	38
161	Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. <i>Aids</i> , 2000, 14, 1709-1715.	1.0	38
162	Effects of Intermittent Interleukin-2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi-Species Expression. <i>Journal of Infectious Diseases</i> , 2000, 182, 1063-1069.	1.9	31

#	ARTICLE	IF	CITATIONS
163	Longitudinal Changes in CD4+T Cell Antigen Receptor Diversity and Naive/Memory Cell Phenotype during 9 to 26 Months of Antiretroviral Therapy of HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1877-1886.	0.5	23
164	Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thr→Gly) at Codon 69. <i>Journal of Virology</i> , 2000, 74, 10958-10964.	1.5	80
165	A Randomized Trial of High-versus Low-Dose Subcutaneous Interleukin-2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 1999, 179, 849-858.	1.9	149
166	Re-emergence of HIV after stopping therapy. <i>Nature</i> , 1999, 401, 874-875.	13.7	390
167	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. <i>Nature Medicine</i> , 1999, 5, 651-655.	15.2	400
168	Atovaquone Suspension in HIV-Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP-SMX Interaction Study. <i>Pharmacotherapy</i> , 1999, 19, 1050-1056.	1.2	41
169	HIV-1 replication in patients with undetectable plasma virus receiving HAART. <i>Lancet</i> , The, 1999, 353, 119-120.	6.3	142
170	Comparison of the Quantiplex Version 3.0 Assay and a Sensitized Amplicor Monitor Assay for Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma Samples. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3612-3614.	1.8	37
171	Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. <i>Nature Medicine</i> , 1998, 4, 852-856.	15.2	115
172	Human immunodeficiency virus disease: Changing patterns of intraocular inflammation. <i>American Journal of Ophthalmology</i> , 1998, 125, 374-382.	1.7	62
173	Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins. <i>Journal of Experimental Medicine</i> , 1997, 185, 1381-1386.	4.2	126
174	Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. <i>Immunological Reviews</i> , 1997, 160, 43-54.	2.8	187
175	HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. <i>Nature Medicine</i> , 1997, 3, 533-540.	15.2	501
176	HIV antivirals and immune recovery. <i>Nature Medicine</i> , 1997, 3, 704-704.	15.2	0
177	Immune reconstitution in HIV infection. <i>Current Opinion in Immunology</i> , 1997, 9, 568-572.	2.4	39
178	Immune-based therapies in HIV infection. <i>Aids</i> , 1996, 10, S159-164.	1.0	16
179	Inhibition of Immunoreactive Tumor Necrosis Factor- $\alpha$ by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 1996, 174, 63-68.	1.9	71
180	Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. <i>New England Journal of Medicine</i> , 1996, 335, 1350-1356.	13.9	429

#	ARTICLE	IF	CITATIONS
181	Biologic Response Modifiers (Interleukins and Interferons)., 1996, , 493-511.		2
182	Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. <i>Nature Medicine</i> , 1995, 1, 330-336.	15.2	372
183	Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection – A Preliminary Study. <i>New England Journal of Medicine</i> , 1995, 332, 567-575.	13.9	433
184	A unique syndrome of immunodeficiency and autoimmunity associated with absent T cell CD2 expression. <i>Journal of Clinical Immunology</i> , 1994, 14, 359-367.	2.0	8
185	A Phase I Study of Interferon- $\gamma$ 2b in Combination with Interleukin-2 in Patients with Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1994, 169, 981-989.	1.9	33
186	Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. <i>Journal of Clinical Immunology</i> , 1993, 13, 185-192.	2.0	16
187	Immunologic Approaches to the Therapy of HIV-1 Infection. <i>Annals of the New York Academy of Sciences</i> , 1993, 685, 687-696.	1.8	5
188	A Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-infected Identical Twins. <i>Human Gene Therapy</i> , 1993, 4, 659-680.	1.4	29
189	Indeterminate western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure. <i>Journal of Clinical Immunology</i> , 1992, 12, 185-192.	2.0	16
190	Immunologic Abnormalities in HIV Infection. <i>Hematology/Oncology Clinics of North America</i> , 1991, 5, 215-228.	0.9	19
191	A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1991, 325, 1534-1538.	13.9	82
192	Effect of Aerosolized Pentamidine Prophylaxis on the Diagnosis of Pneumocystis carinii Pneumonia by Induced Sputum Examination in Patients Infected with the Human Immunodeficiency Virus. <i>The American Review of Respiratory Disease</i> , 1991, 144, 760-764.	2.9	69
193	Syngeneic Bone Marrow Transplantation and Adoptive Transfer of Peripheral Blood Lymphocytes Combined with Zidovudine in Human Immunodeficiency Virus (HIV) Infection. <i>Annals of Internal Medicine</i> , 1990, 113, 512.	2.0	65
194	Laboratory Methods in the Diagnosis and Prognostic Staging of infection with Human Immunodeficiency Virus Type 1. <i>Clinical Infectious Diseases</i> , 1990, 12, 912-930.	2.9	39
195	The immunology of HIV infection. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 1202-1205.	0.6	8
196	Effects of interferon- $\gamma$ in patients with aids-associated Kaposi's sarcoma are related to blood interferon levels and dose. <i>Cytokine</i> , 1990, 2, 247-252.	1.4	16
197	Acquired Immunodeficiency Syndrome. <i>Dermatologic Clinics</i> , 1990, 8, 771-786.	1.0	5
198	Interferon- $\gamma$ in Patients with Asymptomatic Human Immunodeficiency Virus (HIV) Infection. <i>Annals of Internal Medicine</i> , 1990, 112, 805.	2.0	212

#	ARTICLE	IF	CITATIONS
199	A phase I trial of recombinant human interferon- $\beta$ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). <i>Journal of Clinical Immunology</i> , 1989, 9, 351-361.	2.0	37
200	Zidovudine in Patients with Human Immunodeficiency Virus (HIV) Infection and Kaposi Sarcoma. <i>Annals of Internal Medicine</i> , 1989, 111, 41.	2.0	85
201	Host defense against <i>Mycobacterium-avium</i> complex. <i>Journal of Clinical Immunology</i> , 1988, 8, 234-243.	2.0	58
202	ANTI-RETROVIRAL EFFECTS OF INTERFERON- $\beta$ IN AIDS-ASSOCIATED KAPOSI'S SARCOMA. <i>Lancet, The</i> , 1988, 332, 1218-1222.	6.3	246
203	Diagnosis of <i>Pneumocystis carinii</i> Pneumonia: Improved Detection in Sputum with Use of Monoclonal Antibodies. <i>New England Journal of Medicine</i> , 1988, 318, 589-593.	13.9	352
204	Trimetrexate for the Treatment of <i>Pneumocystis carinii</i> Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1987, 317, 978-985.	13.9	243
205	Combination chemotherapy of disseminated kaposi's sarcoma in patients with the acquired immune deficiency syndrome. <i>American Journal of Medicine</i> , 1987, 82, 456-462.	0.6	65
206	Peripheral t cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. <i>American Journal of Medicine</i> , 1987, 82, 539-545.	0.6	72
207	Clinical Pharmacokinetics of Suramin in Patients With HTLV-III/LAV Infection. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 22-26.	1.0	130
208	Immunologic Reconstitution in the Acquired Immunodeficiency Syndrome. <i>Annals of Internal Medicine</i> , 1985, 103, 714.	2.0	42
209	Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1985, 313, 79-84.	13.9	760
210	EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO. <i>Lancet, The</i> , 1985, 326, 627-630.	6.3	190
211	Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. <i>American Journal of Medicine</i> , 1985, 78, 417-422.	0.6	180
212	Ophthalmic Involvement in Acquired Immunodeficiency Syndrome. <i>Ophthalmology</i> , 1984, 91, 1092-1099.	2.5	321
213	Kaposi's Sarcoma of the Head and Neck in the Acquired Immune Deficiency Syndrome. <i>Otolaryngology - Head and Neck Surgery</i> , 1984, 92, 255-260.	1.1	30
214	Partial Immune Reconstitution in a Patient with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1984, 311, 1099-1103.	13.9	67
215	Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1983, 309, 453-458.	13.9	1,653